The bortezomib compound increased the protein levels of Cav3.2 in DRG and induced peripheral neuropathy through the upregulation of USP5 that inhibits proteasomal degradation of Cav3.2 in mice (Tomita et al., 2020). The gene discussed is CACNA1H; the disease is peripheral neuropathy.